Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543
The ’149 patent covers CTP-543, Concert’s investigational drug candidate for the treatment of alopecia areata. The inter partes review (IPR) proceeding does not prohibit Concert from developing CTP-543 and does not affect other intellectual property protection that the Company is pursuing, including a new Notice of Allowance from the U.S. Patent and Trademark Office (PTO) covering pharmaceutical compositions of CTP-543 and methods of treating alopecia areata with CTP-543.
“We are pleased that the Federal Circuit granted our motion and look forward to reconsideration by a new panel of PTAB judges. We continue to believe that we have strong arguments for the validity of the ’149 patent,” stated
The CAFC’s grant of the Company’s motion will take effect on
Documents relating to the IPR can be accessed on Concert’s website at: https://www.concertpharma.com/platform/intellectual-property/.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including, among others, statements about anticipated IPR proceedings, and any other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and timing of future clinical trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations regarding the CAFC’s grant of our motion to vacate and remand the PTAB’s decision to invalidate the ’149 patent and any related proceedings, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our most recent Quarterly Report on Form 10-Q filed with the
Justine Koenigsberg (investors)
Concert Pharmaceuticals, Inc.
Kathryn Morris (media)
The Yates Network